BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Biotech catalysts in 2025-04

190 industry Phase 2/3 trial readout(s) and 55 FDA decision event(s). Readouts include completed (ACTUAL) and still-estimated primary completion dates in this month, any status.

← 2025-03 | 2025-05 →

FDA decision events

DateEventStatusCompanyDrugSource
2025-04-02Complete response lettercomplete responseAmneal EU, Limited AMRXphenylephrine hydrochloride in sodium chlorideCRL 2025-04-02: Amneal EU, Limited NDA 218345 (phenylephrine hydrochloride in sodium chloride injection)
2025-04-02Complete response lettercomplete responseAldeyra Therapeutics, Inc. ALDXReproxalap OphthalmicCRL 2025-04-02: Aldeyra Therapeutics, Inc. NDA 216442 (Reproxalap Ophthalmic Solution, °®)
2025-04-02FDA approvalapprovedNOVARTIS NVSVANRAFIAApproved 2025-04-02: VANRAFIA (NDA219208 ORIG1)
2025-04-03FDA approvalapprovedB BRAUN MEDICALPIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE IN DUPLEX CONTAINERApproved 2025-04-03: PIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE IN DUPLEX CONTAINER (NDA206056 ORIG1)
2025-04-03FDA approvalapprovedVIELA BIOUPLIZNAApproved 2025-04-03: UPLIZNA (BLA761142 SUPPL3)
2025-04-04FDA approvalapprovedCUBIST PHARMS LLCSIVEXTROApproved 2025-04-04: SIVEXTRO (NDA205435 SUPPL16)
2025-04-04FDA approvalapprovedCUBIST PHARMS LLCSIVEXTROApproved 2025-04-04: SIVEXTRO (NDA205436 SUPPL13)
2025-04-07FDA approvalapprovedELI LILLY AND CO LLYCYRAMZAApproved 2025-04-07: CYRAMZA (BLA125477 SUPPL49)
2025-04-07FDA approvalapprovedAMGEN INC AMGNAMJEVITAApproved 2025-04-07: AMJEVITA (BLA761024 SUPPL23)
2025-04-07FDA approvalapprovedOCULAR THERAPEUTIX OCULDEXTENZAApproved 2025-04-07: DEXTENZA (NDA208742 SUPPL13)
2025-04-08FDA approvalapprovedBRISTOL MYERS SQUIBB BMYYERVOYApproved 2025-04-08: YERVOY (BLA125377 SUPPL135)
2025-04-08FDA approvalapprovedBRISTOL MYERS SQUIBB BMYOPDIVOApproved 2025-04-08: OPDIVO (BLA125554 SUPPL132)
2025-04-09FDA approvalapprovedBIOCON BIOLOGICS INCJOBEVNEApproved 2025-04-09: JOBEVNE (BLA761175 ORIG1)
2025-04-09FDA approvalapprovedBAYER HLTHCAREVITRAKVIApproved 2025-04-09: VITRAKVI (NDA210861 SUPPL12)
2025-04-09FDA approvalapprovedBAYER HEALTHCAREVITRAKVIApproved 2025-04-09: VITRAKVI (NDA211710 SUPPL10)
2025-04-10FDA approvalapprovedARGENX BVVYVGART HYTRULOApproved 2025-04-10: VYVGART HYTRULO (BLA761304 SUPPL8)
2025-04-10FDA approvalapprovedRUBICON RESEARCHLOPRESSORApproved 2025-04-10: LOPRESSOR (NDA219373 ORIG1)
2025-04-10FDA approvalapprovedMIRUM MIRMLIVMARLIApproved 2025-04-10: LIVMARLI (NDA219485 ORIG1)
2025-04-10FDA approvalapprovedJANSSEN BIOTECHDARZALEXApproved 2025-04-10: DARZALEX (BLA761036 SUPPL54)
2025-04-11FDA approvalapprovedBRISTOL MYERS SQUIBB BMYYERVOYApproved 2025-04-11: YERVOY (BLA125377 SUPPL133)
2025-04-11FDA approvalapprovedBRISTOL MYERS SQUIBB BMYOPDIVOApproved 2025-04-11: OPDIVO (BLA125554 SUPPL129)
2025-04-15FDA approvalapprovedMERCK SHARP DOHME MRKWELIREGApproved 2025-04-15: WELIREG (NDA215383 SUPPL10)
2025-04-15FDA approvalapprovedMERCK SHARP DOHME MRKWELIREGApproved 2025-04-15: WELIREG (NDA215383 SUPPL11)
2025-04-15FDA approvalapprovedNEURELIS INCVALTOCOApproved 2025-04-15: VALTOCO (NDA211635 SUPPL10)
2025-04-15FDA approvalapprovedRECORDATI RAREISTURISAApproved 2025-04-15: ISTURISA (NDA212801 SUPPL3)
2025-04-15FDA approvalapprovedCMG PHARM CO LTDMEZOFYApproved 2025-04-15: MEZOFY (NDA211448 ORIG1)
2025-04-16FDA approvalapprovedAVYXA HOLDINGSPOSFREAApproved 2025-04-16: POSFREA (NDA203050 SUPPL3)
2025-04-17FDA approvalapprovedBRISTOL BMYCAMZYOSApproved 2025-04-17: CAMZYOS (NDA214998 SUPPL10)
2025-04-17FDA approvalapprovedBRISTOL MYERS SQUIBB BMYELIQUISApproved 2025-04-17: ELIQUIS (NDA202155 SUPPL39)
2025-04-17FDA approvalapprovedBRISTOL MYERS SQUIBB BMYELIQUISApproved 2025-04-17: ELIQUIS (NDA202155 SUPPL40)
2025-04-17FDA approvalapprovedBRISTOL BMYELIQUIS; ELIQUIS SPRINKLEApproved 2025-04-17: ELIQUIS; ELIQUIS SPRINKLE (NDA220073 ORIG1)
2025-04-17FDA approvalapprovedREGENERON PHARMACEUTICALS REGNDUPIXENTApproved 2025-04-17: DUPIXENT (BLA761055 SUPPL51)
2025-04-21FDA approvalapprovedMITCHELL WEDLING SUPPLYCARBON DIOXIDE USPApproved 2025-04-21: CARBON DIOXIDE, USP (NDA220461 ORIG1)
2025-04-21FDA approvalapprovedMERCK SHARP DOHME MRKKEYTRUDAApproved 2025-04-21: KEYTRUDA (BLA125514 SUPPL174)
2025-04-22FDA approvalapprovedBEIGENETEVIMBRAApproved 2025-04-22: TEVIMBRA (BLA761232 SUPPL2)
2025-04-22FDA approvalapprovedBEIGENETEVIMBRAApproved 2025-04-22: TEVIMBRA (BLA761232 SUPPL12)
2025-04-22FDA approvalapprovedBEIGENETEVIMBRAApproved 2025-04-22: TEVIMBRA (BLA761232 SUPPL5)
2025-04-22FDA approvalapprovedBEIGENETEVIMBRAApproved 2025-04-22: TEVIMBRA (BLA761232 SUPPL3)
2025-04-22FDA approvalapprovedBEIGENETEVIMBRAApproved 2025-04-22: TEVIMBRA (BLA761232 SUPPL11)
2025-04-22FDA approvalapprovedBEIGENETEVIMBRAApproved 2025-04-22: TEVIMBRA (BLA761232 SUPPL6)
2025-04-22FDA approvalapprovedNANJING DELOVAQAMZOVAApproved 2025-04-22: QAMZOVA (NDA217593 ORIG1)
2025-04-23FDA approvalapprovedAKESO BIOPHARMAPENPULIMAB-KCQXApproved 2025-04-23: PENPULIMAB-KCQX (BLA761258 ORIG1)
2025-04-23FDA approvalapprovedPFIZER PFEIBRANCEApproved 2025-04-23: IBRANCE (NDA207103 SUPPL20)
2025-04-23FDA approvalapprovedPFIZER PFEIBRANCEApproved 2025-04-23: IBRANCE (NDA212436 SUPPL8)
2025-04-25Complete response lettercomplete responseTelix Pharmaceuticals (US) Inc. TLX(floretyrosine F 18) injectionCRL 2025-04-25: Telix Pharmaceuticals (US) Inc. NDA 218592 ((floretyrosine F 18) injection)
2025-04-25Complete response lettercomplete responseFresenius Kabi USA, LLCCRL 2025-04-25: Fresenius Kabi USA, LLC NDA 215818
2025-04-25Complete response lettercomplete responseUniversity of California San FranciscoFloretyrosine F 18 InjectionCRL 2025-04-25: University of California San Francisco NDA 218353 (Floretyrosine F 18 Injection)
2025-04-28FDA approvalapprovedABBVIE ABBVRINVOQApproved 2025-04-28: RINVOQ (NDA211675 SUPPL25)
2025-04-29FDA approvalapprovedJANSSEN BIOTECHIMAAVYApproved 2025-04-29: IMAAVY (BLA761430 ORIG1)
2025-04-30FDA approvalapprovedSATSUMA PHARMSATZUMIApproved 2025-04-30: ATZUMI (NDA217901 ORIG1)
2025-04-30FDA approvalapprovedCELLTRION, INC.STEQEYMAApproved 2025-04-30: STEQEYMA (BLA761338 ORIG2)
2025-04-30FDA approvalapprovedSAMSUNG BIOEPIS CO LTDPYZCHIVAApproved 2025-04-30: PYZCHIVA (BLA761373 ORIG2)
2025-04-30FDA approvalapprovedFRESENIUS KABI USAOTULFIApproved 2025-04-30: OTULFI (BLA761379 ORIG2)
2025-04-30FDA approvalapprovedBIOCON BIOLOGICS INCYESINTEKApproved 2025-04-30: YESINTEK (BLA761406 ORIG2)
2025-04-30FDA approvalapprovedSAMSUNG BIOEPIS CO LTDPYZCHIVAApproved 2025-04-30: PYZCHIVA (BLA761425 ORIG2)

Trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2025-04 est.P2/P3Johnpro Biotech, Inc.NCT03008148 Phase II/III Trial of CCRT With or Without JP001 for Newly Diagnosed GBMGlioblastomaunknown288
2025-04 est.P1/P2Oblato, Inc.NCT03649464 Investigation of Oral OKN-007 in Recurrent High-grade Glioma ParticipantsGlioblastoma; Astrocytoma; Oligodendrogliomawithdrawn
2025-04 est.P3Angiodynamics, Inc. ANGONCT03899636 A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic CancerStage III Pancreatic Canceractive not recruiting528
2025-04 est.P3MallinckrodtNCT04128462 MNK-6105 for Patients With Cirrhosis and High Ammonia Levels Affecting Brain FunctionHepatic Encephalopathywithdrawn
2025-04 est.P3EMSNCT04603508 Efficacy and Safety of Berlim 25/10 Association in the Treatment of Type II Diabetes Mellitus and DyslipidemiaType 2 Diabetes Mellitus; Dyslipidemiaunknown240
2025-04 est.P1/P2Nelum CorpNCT04827953 Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic CancerPancreatic Ductal Adenocarcinomaactive not recruiting28
2025-04 est.P1/P2Suzhou Kintor Pharmaceutical Inc,NCT04984668 A Phase Ib/II Study of GT90001 Combined With KN046 in Solid TumorsSolid Tumorunknown216
2025-04 est.P2Beijing InnoCare Pharma Tech Co., Ltd.NCT05552937 Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCLDLBCLrecruiting50
2025-04 est.P1/P2Shandong Qilu Stem Cells Engineering Co., Ltd.NCT05794425 Clinical Study of UCB Combined With UC-MSCs in the Treatment of Bone Marrow Failure DisordersBone Marrow Failure Disordersunknown100
2025-04 est.P3Livzon Pharmaceutical Group Inc.NCT06110676 A Study to Evaluate the Efficacy and Safety of LZM012Psoriasisunknown918
2025-04 est.P3Natural Wellness EgyptNCT06141200 NW Roselle in Grade 1 Essential Hypertension: Phase III Clinical TrialEssential Hypertensionunknown286
2025-04 est.P2Qilu Pharmaceutical Co., Ltd.NCT06261359 A Study of CEND-1 With Chemotherapy as First-Line Therapy in Patients With Pancreatic Ductal AdenocarcinomaPancreatic Ductal Adenocarcinoma (PDAC)unknown120
2025-04 est.P1/P2Eyestem Research Pvt. Ltd.NCT06394232 Safety & Efficacy of Eyecyte-RPE™ in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration.Retinal Disease; Macular Degeneration; Age-Related Macular Degeneration; Geographic Atrophy; Eye Disrecruiting54
2025-04 est.P2DermBiont, Inc.NCT06454747 Randomized Study Using SM-030 Gel for Adults With MelasmaMelasmarecruiting138
2025-04 est.P2Jiangsu HengRui Medicine Co., Ltd.NCT06731829 A Study for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Brain and/or Spinal Cord ConditionsFor Contrast-enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System (CNS) Lesionsnot yet recruiting78
2025-04-01P3Sanofi SNYNCT03560466 Assessment of the Safety and Efficacy of Dupilumab in Children With Asthma (Liberty Asthma Excursion)Asthmacompleted378
2025-04-01P1/P2Genmab GMABNCT03917381 GEN1046 Safety Trial in Patients With Malignant Solid TumorsSolid Tumorsterminated429
2025-04-01P1/P2Incyte Corporation INCYNCT04455841 INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative DisordersAnemia; Post-essential Thrombocythemia Myelofibrosis; Post-polycythemia Vera Myelofibrosiscompleted84
2025-04-01P1/P2Servier Bio-Innovation LLCNCT05159388 A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody) in Patients With Solid TumorsSolid Tumorterminated46
2025-04-01 est.P2Suzhou Kintor Pharmaceutical Inc,NCT05178043 GT90001 Plus Nivolumab in Patients With Advanced Hepatocellular CarcinomaHepatocellular Carcinoma; HCCunknown5
2025-04-01 est.P1/P2Beijing Immunochina Medical Science & Technology Co., Ltd.NCT05309213 Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic LeukemiaLeukemiaunknown58
2025-04-01 est.P2/P3NuvOx LLC NUOXNCT05389748 NanO2 for Large Vessel Occlusion StrokeIschemic Strokeunknown300
2025-04-01P1/P2Daiichi SankyoNCT05638802 A Study of DS-7011a in Patients With Systemic Lupus ErythematosusSystemic Lupus Erythematosuscompleted26
2025-04-01 est.P3CanSino Biologics Inc.NCT05951725 A Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed(DTcP)Diphtheria, Tetanus and Acellular Pertussisactive not recruiting2520
2025-04-01 est.P1/P2Guangzhou Gloria Biosciences Co., Ltd.NCT05978401 Safety, Tolerability, and Efficacy of GLS-012 and GLS-010 in Patients With Advanced Non-Small Cell Lung CancerAdvanced Non-Small Cell Lung Cancerunknown152
2025-04-01P2Eli Lilly and Company LLYNCT06176768 A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque PsoriasisPlaque Psoriasiscompleted33
2025-04-01 est.P2Fujian Akeylink Biotechnology Co., Ltd.NCT06263959 A Randomized, Double-blind, Placebo-controlled Phase IIa Clinical Study to Evaluate the Safety and Efficacy of GST-HG131 Tablets in Patients With Chronic HepatiChronic Hepatitis Brecruiting45
2025-04-01 est.P3CSPC Ouyi Pharmaceutical Co., Ltd.NCT06383702 A Study to Evaluate Pregabalin in Painful Diabetic Peripheral NeuropathyPainful Diabetic Neuropathyunknown358
2025-04-01P2Medex d.o.o.NCT06573814 The Effects of Bio Gelee Royale Forte on Immune Health in Healthy AdultsUpper Respiratory Tract Infection; URTIcompleted100
2025-04-02P3Prothena Biosciences Ltd. PRTANCT04973137 A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL AmyloidosisLight Chain (AL) Amyloidosisterminated208
2025-04-02P1/P2GlaxoSmithKlineNCT05089630 A Study of Safety and Immune Response to Different Doses of a Cytomegalovirus Vaccine in Healthy AdultsCytomegalovirus Infectionscompleted333
2025-04-02P3Lyra TherapeuticsNCT05295459 Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis in Adults (ENLIGHTEN 2)Chronic Sinusitis; Chronic Rhinosinusitis (Diagnosis)completed182
2025-04-02P3Marinus PharmaceuticalsNCT05604170 Open-label Study of Adjunctive GNX Treatment in Children and Adults With TSC-related EpilepsyTuberous Sclerosis Complexterminated117
2025-04-02P3Novo Nordisk A/S NVONCT06041217 A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight RangeOverweight; Obesitycompleted242
2025-04-02P3Tasly Pharmaceutical Group Co., LtdNCT06068478 A Study to Evaluate Efficacy and Safety of Qingzhu Granules in the Treatment of Acute Gouty ArthritisGouty Arthritiscompleted472
2025-04-02P2Haisco Pharmaceutical Group Co., Ltd.NCT06561841 A Study to Evaluate the Efficacy and Safety of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria(PNH)Paroxysmal Nocturnal Hemoglobinuria (PNH)completed47
2025-04-03P2Takeda TAKNCT03196427 Long-term Safety With Vedolizumab Intravenous (IV) in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)Ulcerative Colitis; Crohn's Diseasecompleted59
2025-04-03P3AstraZeneca AZNNCT03528694 Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder CancerNon-muscle-invasive Bladder Canceractive not recruiting1018
2025-04-03P3Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USANCT04811092 Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13)Pulmonary Arterial Hypertensionterminated321
2025-04-03P2GemVax & KaelNCT05189210 GV1001 Subcutaneous(SC) for the Treatment of Mild to Moderate Alzheimer's Disease (AD)Mild to Moderate Alzheimer's Diseasecompleted199
2025-04-03P1/P2BerGenBio ASANCT05469178 A Clinical Study of Bemcentinib With Standard of Care Chemoimmunotherapy in Untreated Advanced/Metastatic Non-small Cell Lung Cancer Patients With a Mutation inCarcinoma, Non-Small-Cell Lungterminated26
2025-04-03P1/P2Alnylam Pharmaceuticals ALNYNCT05761301 A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DMType 2 Diabetes Mellitus (T2DM)terminated49
2025-04-03P1/P2Nanjing Leads Biolabs Co.,LtdNCT05779163 A Phase I/II Clinical Trial of LBL-033 in the Treatment of Advanced Malignant TumorsAdvanced Malignant Tumorscompleted26
2025-04-03P3Eli Lilly and Company LLYNCT05971940 A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise AloneType 2 Diabetescompleted559
2025-04-03P2Perfuse Therapeutics, Inc.NCT06003751 A Study of PER-001 in Participants With Diabetic RetinopathyDiabetic Retinopathycompleted27
2025-04-03P1/P2Novakand Pharma ABNCT06087289 A Study to Evaluate the Safety of KAND567, in Combination With Carboplatin Therapy, in Women With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary PeritEpithelial Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancercompleted18
2025-04-03P3Opus Genetics, Inc IRDNCT06542497 Evaluate Efficacy and Safety of POS to Improve Distance-corrected Near Visual in Participants With PresbyopiaPresbyopiacompleted569
2025-04-03P2Inventprise Inc.NCT06790290 Phase 2 Trial to Evaluate Safety and Immunogenicity of Inventprise's (IVT) 25-valent Pneumococcal Conjugate Vaccine (IVT PCV-25) in Healthy InfantsPneumococcal Disease, Invasiveactive not recruiting421
2025-04-04P2CARGO TherapeuticsNCT05972720 A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell LymphomaCancer; Relapsed/Refractory Large B-cell Lymphoma (LBCL)terminated101
2025-04-04P2Pliant Therapeutics, Inc. PLRXNCT06097260 Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary FibrosisIdiopathic Pulmonary Fibrosisterminated320
2025-04-04P2Zomagen Biosciences Ltd.NCT06556173 Phase 2a Study of VTX3232 in Parkinson's DiseaseIdiopathic Parkinson Diseasecompleted11
2025-04-04P3BioNet-Asia Co., Ltd.NCT06798831 Study Evaluating the Safety of a Recombinant Acellular Pertussis Vaccine in AdultsPertussis Vaccineactive not recruiting2399
2025-04-07P2/P3Sun Pharmaceutical Industries LimitedNCT03997786 A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque PsoriasisModerate-to-severe Chronic Plaque Psoriasisactive not recruiting135
2025-04-07P3AstraZeneca AZNNCT04931563 Anifrolumab Asian PhIII Efficacy Study for Systemic Lupus Erythematosus (SLE)Active Systemic Lupus Erythematosuscompleted277
2025-04-07P3Merck Sharp & Dohme LLC MRKNCT05952869 A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017/CORALreef HeFH)Hypercholesterolemia; Familial Hypercholesterolemiacompleted303
2025-04-07P3Addpharma Inc.NCT06291207 A Study to Evaluate the Efficacy and Safety of AD-224Hypertension,Essentialcompleted254
2025-04-07P3Shanghai Ark Biopharmaceutical Co., Ltd.NCT06775405 A Study to Confirm the Effectiveness and Safety of AK0529 in Treating RSV Infections in Hospitalized InfantsRespiratory Synctial Virus Infectionscompleted180
2025-04-08P3AbbVie ABBVNCT02632175 Long-term Safety and Efficacy Study of Adalimumab in Pediatric Subjects With Ulcerative ColitisUlcerative Colitiscompleted59
2025-04-08P3Alexion Pharmaceuticals, Inc.NCT04512235 A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)AL Amyloidosisactive not recruiting281
2025-04-08P3Anterogen Co., Ltd.NCT04612465 Clinical Study to Evaluate Efficacy and Safety of ASC and Fibringlue or Fibringlue in Patients With Crohn's FistulaCrohn's Fistulaactive not recruiting46
2025-04-08P3Janssen Research & Development, LLCNCT06514742 A Study of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate ReDepressive Disorder, Major; Anhedoniaterminated101
2025-04-08P2Sanofi SNYNCT06949358 A Study to Evaluate Safety and Tolerability of Olipudase Alfa in Pediatric and Adult Participants With Acid Sphingomyelinase Deficiency (ASMD) Who Completed theAcid Sphingomyelinase Deficiencycompleted3
2025-04-09P1/P2Otsuka Pharmaceutical Co., Ltd.NCT04649073 Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple MyelomaMultiple Myeloma (MM)terminated11
2025-04-09P3Lipogems International spaNCT05660772 Microfragmented Adipose Tissue Compared to Corticosteroid Injection for the Treatment of Knee OsteoarthritisKnee Osteoarthritis; Osteo Arthritis Kneecompleted173
2025-04-09P2Recognify Life SciencesNCT05686239 A Study to Evaluate RL-007 in the Treatment of Cognitive Impairment Associated With Schizophrenia (CIAS)Cognitive Impairment Associated With Schizophrenia (CIAS); Cognitive Impairment; Schizophreniacompleted242
2025-04-09P2Merck Sharp & Dohme LLC MRKNCT06099782 A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MKNon-Small Cell Lung Cancer; Renal Cell Carcinoma; Melanomaactive not recruiting147
2025-04-09P2Neumora Therapeutics, Inc. NMRANCT06429722 To Evaluate the Effects of NMRA-335140 on Symptoms of Major Depression in Participants With Bipolar II Disorder.Major Depressive Episode Associated With Bipolar II Disordercompleted18
2025-04-09P3Janssen Research & Development, LLCNCT06635135 A Study of Aticaprant Plus an Antidepressant to Prevent Return of Depression Symptoms in Participants With Major Depressive Disorder Who Experience a Loss of InDepressive Disorder, Major; Anhedoniaterminated47
2025-04-10P1/P2Sangamo Therapeutics SGMOQNCT04046224 Dose-Ranging Study of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Disease (STAAR)Fabry Diseasecompleted36
2025-04-10P3Astellas Pharma Global Development, Inc.NCT05536297 Avacincaptad Pegol Open-Label Extension for Patients With Geographic AtrophyGeographic Atrophy; Age-Related Macular Degenerationcompleted278
2025-04-10 est.P1/P2Biotheus Inc.NCT05839106 Phase I/IIa Study for PM1032 in the Treatment of Patients With Advanced Solid TumorsAdvanced Tumorunknown200
2025-04-10P2Bristol-Myers Squibb BMYNCT06101134 A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose CombMelanomaactive not recruiting100
2025-04-10P2Novo Nordisk A/S NVONCT06326060 A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose WeightObesitycompleted354
2025-04-10P2Sunhawk Vision Biotech, Inc.NCT06381986 Efficacy and Safety of SHJ002 Ophthalmic Solution in the Treatment of Corneal Erosion in Sjogren's PatientsCorneal Erosioncompleted116
2025-04-11P3Merck Sharp & Dohme LLC MRKNCT04029480 Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059)Type 2 Diabetes Mellituscompleted166
2025-04-11P3Nicox Ophthalmics, Inc.NCT04630808 MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular HypertensionOpen Angle Glaucoma; Ocular Hypertensioncompleted696
2025-04-11P3Sanofi SNYNCT04701983 Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)Chronic Obstructive Pulmonary Diseasecompleted1127
2025-04-11P3Novartis Pharmaceuticals NVSNCT04930094 Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GGiant Cell Arteritis (GCA)completed354
2025-04-11P3Amgen AMGNNCT06224192 A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe Atopic DermatitisAtopic Dermatitiscompleted151
2025-04-11P2/P3Boehringer IngelheimNCT06241573 A Study to Test Long-term Treatment With Spesolimab in People With a Skin Condition Disease Called Hidradenitis Suppurativa (HS) Who Took Part in a Previous StuHidradenitis Suppurativa (HS)terminated39
2025-04-11P2Veru Inc. VERUNCT06282458 Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight MgmtMuscle Loss; Obesitycompleted168
2025-04-12P3ModernaTX, Inc.NCT05815498 A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19COVID-19completed13553
2025-04-12P3Summit Therapeutics SMMTNCT06396065 Phase III Study of AK112 for NSCLC PatientsNon-Squamous Non-small Cell Lung Canceractive not recruiting420
2025-04-14P2CelgeneNCT02494258 A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological DisordersHematologic Neoplasm; Neoplasms; Hematologic Malignanciescompleted5
2025-04-14P3Instituto Grifols, S.A.NCT03702920 Short-term Survival of Subjects With Acute-on-chronic Liver Failure After Plasma Exchange With Human Serum Albumin 5%Acute-On-Chronic Liver Failureterminated274
2025-04-14P3PolyPid Ltd. PYPDNCT04411199 D-PLEX 312 - Safety and Efficacy of D-PLEX in the Prevention of Post Abdominal Surgery Incisional Infection (SHIELD II)Surgical Site Infection; Colon Surgery; Abdominal Surgery; Post-Op Infectioncompleted975
2025-04-14P2Orano Med LLCNCT05153772 Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor PatientsNeuroendocrine Tumorsactive not recruiting69
2025-04-14P3Novo Nordisk A/S NVONCT05813912 A Research Study to See How a New Weekly Insulin, Insulin Icodec When Given Along With Semaglutide Helps in Reducing the Blood Sugar Level in Patients With TypeDiabetes Mellitus, Type 2completed148
2025-04-14P3Alexion Pharmaceuticals, Inc.NCT05886244 Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) in ChinaParoxysmal Nocturnal Hemoglobinuriacompleted25
2025-04-14P3Janssen Research & Development, LLCNCT06039189 Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque PsoriasisModerate Plaque Psoriasiscompleted338
2025-04-14P2Alto Neuroscience ANRONCT06391593 PD, PK, and Safety of ALTO-203 in Patients With MDDMajor Depressive Disorder; Anhedoniacompleted69
2025-04-15 est.P2Can-Fite BioPharma CANFNCT04697810 Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH)NASH - Nonalcoholic Steatohepatitisunknown114
2025-04-15P3PTC Therapeutics PTCNCT05218655 A Safety Study for Previously Treated Vatiquinone (PTC743) Participants With Inherited Mitochondrial DiseaseInherited Mitochondrial Diseasecompleted101
2025-04-15P2Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. SBFMNCT06099652 Evaluation of 611 in Chinese Adults With Moderate to Severe Chronic Obstructive Pulmonary DiseasePulmonary Disease, Chronic Obstructivecompleted142
2025-04-15P3Colgate Palmolive CLNCT06732466 Evaluation of the Effect of a Toothpaste Containing 0.3% Chlorhexidine in Subjects With Established Dental Plaque and GingivitisGingivitis; Gingivitis and Periodontal Diseases; Gingival Disease; Dental Plaquecompleted80
2025-04-15 est.P3Livzon Pharmaceutical Group Inc.NCT06850480 A Phase III Clinical Trial for Efficacy and Safety Evaluation of JP-1366 Tablets on Reflux EsophagitisReflux Esophagitis (RE)recruiting356
2025-04-15P3Laboratorios Richmond S.A.C.I.F.NCT07448506 Nifedipine Extended-Release in Patients With Mild or Moderate HypertensionHigh Blood Pressure (& [Essential Hypertension])completed50
2025-04-16P3Novartis Pharmaceuticals NVSNCT04717635 Study of Efficacy and Safety of Canakinumab in Japanese Patients With AOSDAdult Onset Still's Diseasecompleted14
2025-04-16P1/P2Arrowhead Pharmaceuticals ARWRNCT05276570 Study of ARO-RAGE in Healthy Subjects and Patients With Inflammatory Lung DiseaseAsthmacompleted127
2025-04-16P2SensorionNCT05628233 SENS-401 to Prevent the Ototoxicity Induced by Cisplatin in Adult Subjects With a Neoplastic DiseaseHearing Loss Ototoxiccompleted48
2025-04-16P2Tasly Pharmaceutical Group Co., LtdNCT06006689 Efficacy and Safety of QiShen YiQi Dripping Pills in the Treatment of Diabetic Kidney Disease (Syndrome of Qi Deficiency With Blood Stasis)Diabetic Kidney Diseasecompleted228
2025-04-16P3BioMarin Pharmaceutical BMRNNCT06224907 Phase 3 Study for Efficacy and Safety Outcomes Data in Japanese Patients With Severe Hemophilia AHemophilia Aactive not recruiting6
2025-04-16P1/P2Takeda TAKNCT06390995 A Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid TumorsOvarian Cancer; Solid Tumorsactive not recruiting28
2025-04-16P2Gilead Sciences GILDNCT06784973 Study of Obeldesivir to Treat Children With Respiratory Syncytial Virus (RSV) InfectionRSV Infectionterminated4
2025-04-17P1/P2GlaxoSmithKlineNCT04126200 Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (Multiple Myelomaactive not recruiting208
2025-04-17P2Cloudbreak Therapeutics, LLCNCT04884256 Safety and Efficacy Study of CBT-004 in Patients With Vascularized PingueculaPingueculacompleted88
2025-04-17P2Longbio PharmaNCT06228560 Efficacy and Safety of LP-003 in Patients With CSU Who Remain Symptomatic Despite Antihistamine (H1) TreatmentChronic Spontaneous Urticariacompleted202
2025-04-17P3Opus Genetics, Inc IRDNCT06349759 Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual DisturbancesMesopic Vision; Night Vision Losscompleted200
2025-04-17P2Changchun GeneScience Pharmaceutical Co., Ltd.NCT06726850 Clinical Study to Evaluate the Efficacy and Safety of GS1-144 Tablets in the Treatment of Moderate to Severe Vasomotor Symptoms in Chinese Postmenopausal Women.Vasomotor Syndromecompleted129
2025-04-17P1/P2GlaxoSmithKlineNCT07084896 Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMMMultiple Myelomaactive not recruiting106
2025-04-17P1/P2GlaxoSmithKlineNCT07150091 Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMMMultiple Myelomaactive not recruiting20
2025-04-17P1/P2GlaxoSmithKlineNCT07150104 Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMMMultiple Myelomaactive not recruiting14
2025-04-17P1/P2GlaxoSmithKlineNCT07217119 Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMMMultiple Myelomaactive not recruiting25
2025-04-17P1/P2GlaxoSmithKlineNCT07217184 Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMMMultiple Myelomaactive not recruiting30
2025-04-18P3Regeneron Pharmaceuticals REGNNCT03088540 Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)Carcinoma,Non-Small-Cell Lung; Lung Carcinomas, Non-Small-Cell; Non-small-cell Lung Carcinoma; Nonsmcompleted712
2025-04-18P3Lynk Pharmaceuticals Co., LtdNCT06277245 A Phase 3 Study of LNK01001 Capsule in Subjects With Moderate to Severe Atopic Dermatitis.Atopic Dermatitiscompleted356
2025-04-18P2AstraZeneca AZNNCT06692764 A Study to Assess the Effect of AZD0780 on Ambulatory Blood PressureAtherosclerotic Cardiovascular Diseasecompleted202
2025-04-18P2TJ Biopharma Co., Ltd.NCT07034209 A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic Characteristics, and Immunogenicity of Plonmarlimab in Subjects With Rheumatic and ImmunHemophagocytic Lymphohistiocytosescompleted18
2025-04-19 est.P2Gwo Xi Stem Cell Applied Technology Co., Ltd.NCT04088058 A Phase II Open-label Single-arm Study to Evaluate the Efficacy and Safety of ADSCs in Subjects With Liver CirrhosisLiver Cirrhosisunknown20
2025-04-20P1/P2Perfuse Therapeutics, Inc.NCT05822245 A Study of PER-001 in Participants With Open-Angle GlaucomaOpen-angle Glaucomacompleted33
2025-04-21P3Sanofi SNYNCT04751487 Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)Chronic Obstructive Pulmonary Diseasecompleted1234
2025-04-21P2/P3Mirati Therapeutics Inc.NCT04887870 Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent StudyAdvanced or Metastatic Solid Malignanciescompleted49
2025-04-21P2Tonix Pharmaceuticals, Inc. TNXPNCT06045793 Comparing Efficacy & Safety Of TNX-1300 To Placebo With UC For Treatment Of Acute Cocaine Intoxication In ED Subjects (CATALYST)Cocaine Use; Cocaine Intoxication; Cocaine Toxicity; Cocaine Abuse; Cocaine Adverse Reactionterminated3
2025-04-22P3Otsuka Pharmaceutical Development & Commercialization, Inc.NCT03238326 Safety and Tolerability of Open-Label Flexible-dose Brexpiprazole as Maintenance Treatment in Adolescents With SchizophreniaSchizophreniacompleted295
2025-04-22P3Equillium EQNCT05263999 A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)Graft Versus Host Disease; GVHD; Acute-graft-versus-host Disease; Acute GVHD; aGVHDterminated158
2025-04-22P3Bio-Thera SolutionsNCT05439629 Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular DegenerationNeovascular (Wet) Age-related Macular Degenerationcompleted488
2025-04-22 est.P2AbbVie ABBVNCT05606757 A Study to Evaluate Adverse Events and Effectiveness of OnabotulinumtoxinA in Participants Undergoing Open Abdominal Ventral Hernia Repair for the Achievement oVentral Hernia; Abdominal Herniawithdrawn
2025-04-22P1/P2GeneCradle IncNCT05901987 Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 2 PatientsSMA IIcompleted29
2025-04-22P2Senhwa Biosciences, Inc.NCT06202521 CX-4945 in Viral Community Acquired PneumoniaCommunity-acquired Pneumonia; SARS-CoV-2 -Associated Pneumonia; Influenza With Pneumoniaterminated45
2025-04-22P2Lassen Therapeutics Inc.NCT06226545 A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye DiseaseThyroid Eye Disease; Graves Ophthalmopathy; Graves Orbitopathy; Thyroid Associated Ophthalmopathy; Ecompleted41
2025-04-22P3Shenzhen Salubris Pharmaceuticals Co., Ltd.NCT07295418 A Study of SAL003 in Participants With Hypercholesterolemia and Mixed DyslipidemiaHyperlipidemiascompleted618
2025-04-23P2Debiopharm International SANCT03723551 Study to Assess Safety, Tolerability and Efficacy of Afabicin in The Treatment of Participants With Bone or Joint Infection Due to StaphylococcusBone or Joint Infectionterminated67
2025-04-23P2/P3Pfizer PFENCT04173273 A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's DiseaseCrohn's Diseaseterminated379
2025-04-23P3Mirum Pharmaceuticals, Inc. MIRMNCT04185363 An Extension Study of Maralixibat in Patients With Progressive Familial Intrahepatic Cholestasis (PFIC)Progressive Familial Intrahepatic Cholestasis (PFIC)completed84
2025-04-23P3Rejoni Inc.NCT05394662 Safety and Effectiveness of Juveena™ Hydrogel System Following Transcervical Gynecologic Procedures (TCGP) At High-Risk for Intrauterine AdhesionsIntrauterine Adhesioncompleted150
2025-04-23P1/P2Clarity Pharmaceuticals LtdNCT05633160 64Cu-SAR-BBN and 67CU SAR-BBN for Identification and Treatment of Gastrin Releasing Peptide Receptor (GRPR)-Expressing Metastatic Castrate Resistant Prostate CaProstatic Neoplasms; Castration-Resistantterminated4
2025-04-23P2Rion Inc.NCT06319287 Phase 2a Multi-Center Prospective, Randomized Trial to Evaluate the Safety & Efficacy of Topical PEP-TISSEEL for Diabetic Foot Ulcers (DFU)Diabetic Foot Ulcercompleted59
2025-04-23P2/P3Lallemand Pharma AGNCT06582589 HEALSea Nasal Spray for Prevention of Infections in ChildrenHealthy Subjectscompleted139
2025-04-23P3Regeneron Pharmaceuticals REGNNCT06602739 A Study to Demonstrate the Effect of REGN5713-5715 on Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Birch Pollen AllergyAllergic Conjunctivitiscompleted54
2025-04-24P3Camurus ABNCT04125836 A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With AcromegalyAcromegalycompleted135
2025-04-24P2Trevi Therapeutics TRVINCT05964335 Cough Reduction in IPF With Nalbuphine ERIdiopathic Pulmonary Fibrosiscompleted165
2025-04-24P3GlaxoSmithKlineNCT06551181 A Study on the Immune Response, Safety and the Occurrence of Respiratory Syncytial Virus (RSV)-Associated Respiratory Tract Illness After Administration of RSV Respiratory Syncytial Virus Infectionscompleted2620
2025-04-24P3Colgate Palmolive CLNCT06732518 Evaluation of the Anti-cavity Efficacy of Three Dentifrices Using an Intra-oral Enamel Demineralization - Remineralization In-Situ ModelEnamel Lesions; Demineralization, Tooth; Remineralization; Dental Cavitycompleted36
2025-04-24P3Daewoong Pharmaceutical Co. LTD.NCT06751121 Study to Evaluate the Efficacy and Safety of DWP14012-based Triple Therapy in Eradication of Helicobacter PyloriHelicobacter Pylori Infection; Helicobacter Pylori Infected Patients; Helicobacter Pylori Infected Scompleted461
2025-04-25P2Sparrow PharmaceuticalsNCT05436652 A Trial of Prednisolone in Combination With SPI-62 or Placebo in Subjects With Polymyalgia Rheumatica (PMR)Polymyalgia Rheumaticacompleted66
2025-04-25P3Janssen Research & Development, LLCNCT05518149 A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD)Depressive Disorder, Majorterminated871
2025-04-25P1/P2ModernaTX, Inc.NCT06033261 A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital HerpGenital Herpescompleted303
2025-04-25P3Viridian Therapeutics, Inc. VRDNNCT06179875 An Open-label Study (OLE) for Non-responders of VRDN-001-101 and VRDN-001-301Thyroid Eye Diseasecompleted139
2025-04-25P2Biohaven Therapeutics Ltd. BHVNNCT06423794 BHV-7000 Open-Label Extension Bipolar Mania StudyBipolar Disorderterminated94
2025-04-26P2Novartis Pharmaceuticals NVSNCT04797000 Study of Efficacy and Safety of Eltrombopag in Lower-risk MDS Patients With Platelet Transfusion DependenceMyelodysplastic Syndromesactive not recruiting36
2025-04-27P2Takeda TAKNCT05673785 A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-PositLymphomaactive not recruiting52
2025-04-27P1/P2Beijing Inno Medicine Co., Ltd.NCT06048588 YN001 in Healthy Subjects and Patients With Coronary AtherosclerosisAtherosclerotic Cardiovascular Diseasecompleted144
2025-04-28P2Galderma R&DNCT04921345 Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic DermatitisModerate-to-Severe Atopic Dermatitiscompleted109
2025-04-28P3Merck Sharp & Dohme LLC MRKNCT04938830 Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007)RSV Infectioncompleted1003
2025-04-28P3AbbVie ABBVNCT05748483 Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events in Adult Participants With MigraineMigrainecompleted545
2025-04-28P1/P2Jiangsu Aidea Pharmaceutical Group Co., Ltd.NCT06719310 Phase Ib/IIa Clinical Study of ACC017 TabletsInfection, Human Immunodeficiency Viruscompleted36
2025-04-29P3Pfizer PFENCT03938792 Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia BHemophilia A; Hemophilia Bcompleted188
2025-04-29P3Novo Nordisk A/S NVONCT04596631 A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 DiabetesDiabetes Mellitus, Type 2completed132
2025-04-29P3Biohaven Pharmaceuticals, Inc. BHVNNCT04693351 A Study to Evaluate the Efficacy and Safety of Adjunctive Troriluzole in Obsessive-Compulsive DisorderObsessive-Compulsive Disordercompleted589
2025-04-29P2Suzhou Ribo Life Science Co. Ltd.NCT05961098 A Study of RBD1016 in CHB ParticipantsChronic Hepatitis bcompleted48
2025-04-29P3Innovent Biologics (Suzhou) Co. Ltd.NCT06049810 IBI112 in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatmentPsoriasiscompleted566
2025-04-30P2CelgeneNCT01946477 Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Multiple Myelomacompleted186
2025-04-30P2Merck Sharp & Dohme LLC MRKNCT04165096 KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small CellCarcinoma, Non-Small-Cell Lungcompleted128
2025-04-30P2DAS-MG, IncNCT04226170 Study of Pyridostigmine With Ondansetron in Subjects With Anti-AchR Positive Myasthenia GravisMyasthenia Gravisterminated2
2025-04-30P1/P2TJ Biopharma Co., Ltd.NCT04322006 A Phase I/II Study of TJ004309 for Advanced Solid TumorAdvanced Solid Tumorcompleted225
2025-04-30 est.P2Zensun Sci. & Tech. Co., Ltd.NCT04859621 Phase II Clinical Trial of Vitamin D3 for Reducing Recurrence of Recurrent Lower Urinary Tract InfectionsRecurrent Urinary Tract Infectionunknown150
2025-04-30 est.P1/P2Cyclacel Pharmaceuticals, Inc.NCT04983810 A Study to Investigate Fadraciclib (CYC065), in Subjects With Advanced Solid Tumors and LymphomaSolid Tumor, Adult; Lymphomaunknown330
2025-04-30 est.P3SandozNCT05070650 Efficacy and Safety of the Combination of Acetylcysteine, Paracetamol and Phenylephrine for the Treatment of Common ColdCommon Coldwithdrawn
2025-04-30P2/P3Zydus Therapeutics Inc.NCT05133336 Saroglitazar Magnesium for Treatment of Primary Biliary CholangitisPrimary Biliary Cholangitiscompleted196
2025-04-30P1/P2Allist Pharmaceuticals, Inc.NCT05194995 JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C MutationAdvanced Colorectal Cancer; Small Intestinal Cancer; Appendiceal Canceractive not recruiting48
2025-04-30 est.P2IO BiotechNCT05280314 Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable TumorsMelanoma; Squamous Cell Carcinoma of Head and Neckrecruiting60
2025-04-30 est.P1/P2Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT05367778 Phase 1/2 Study of HS-10370 in Patients with Advanced Solid TumorsAdvanced Solid Tumorunknown176
2025-04-30P2AkesoNCT05432492 A Study of AK112 in Patients With Unresectable Hepatocellular Carcinoma (HCC)Hepatocellular Carcinomacompleted40
2025-04-30P2Kezar Life Sciences, Inc.NCT05569759 A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA)Autoimmune Hepatitiscompleted24
2025-04-30P1/P2NextCure, Inc. NXTCNCT05572684 A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid TumorsAdvanced or Metastatic Solid Tumors; Microsatellite Instability Low; Microsatellite Instability Highterminated97
2025-04-30 est.P1/P2Innovent Biologics (Suzhou) Co. Ltd.NCT05636215 A First-in-human Study of IBI354 in Subjects with Locally Advanced Unresectable or Metastatic Solid TumorsLocally Advanced Unresectable or Metastatic Solid Tumorsrecruiting368
2025-04-30P1/P2Genfleet Therapeutics (Shanghai) Inc.NCT05756153 A Study of GFH925 in Combination With Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C MutationAdvance Non-small Cell Lung Cancercompleted47
2025-04-30 est.P1/P2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT05765032 Study of SHR-A1921 in Combination With Other Anti-cancer Agents in Patients With Advanced Solid TumorsAdvanced Solid Tumorunknown220
2025-04-30 est.P2Biotheus Inc.NCT05879068 A Study of PM8002 in Combination With Chemotherapy in Patients With SCLCSCLCactive not recruiting99
2025-04-30 est.P1/P2Shanghai Kanda Biotechnology Co., Ltd.NCT05906524 KD6001 in Combination With Anti-PD-1 Antibody±Bevacizumab in Patients With Advanced HCC and Other Solid TumorsAdvanced HCC; Other Solid Tumorsunknown85
2025-04-30P3Almirall, S.A.NCT06135415 A Study to Evaluate the Efficacy and Safety of Tirbanibulin Ointment in Adult Participants With Actinic KeratosisKeratosis, Actiniccompleted280
2025-04-30P1/P2Immuneering Corporation IMRXNCT06208124 A Study of IMM-6-415 in RAS/RAF Mutant Solid TumorsAdvanced Solid Tumor (Phase 1); Pancreas Adenocarcinoma; Non-small Cell Lung Cancer; Malignant Melancompleted30
2025-04-30 est.P1/P2BriaCell Therapeutics Corporation BCTXNCT06471673 A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast CancerBreast Cancer; Breast Tumor; Cancer of Breast; Cancer of the Breast; Malignant Tumor of Breast; Tumounknown18
2025-04-30 est.P2Shanghai Ming Ju Biotechnology Co., Ltd.NCT06479356 CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell LymphomaNon-Hodgkin Lymphoma; Large B-cell Lymphomarecruiting12
2025-04-30P3AO GENERIUMNCT06488664 An Efficacy and Safety Study of GNR-068 (Ustekinumab Biosimilar) and Stelara® in the Treatment of Patients With Moderate to Severe Plaque PsoriasisPlaque Psoriasiscompleted422
2025-04-30P2Huabo Biopharm Co., Ltd.NCT06592274 A Phase 2 Study of HB0017 in Psoriasis PatientsPsoriasis (PsO)completed206
2025-04-30P2Okyo Pharma Ltd OKYONCT06637527 The Study Assessing the Safety and Efficacy of OK-101 Treatment in Subjects With Neuropathic Corneal PainNeuropathic Painterminated18
2025-04-30 est.P1/P2Zhuhai Yufan Biotechnologies Co., LtdNCT06727630 A Phase Ib Study of PRJ1-3024 for Treatment of Advanced or Metastatic MelanomaMelanomaunknown40
2025-04-30P2Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.NCT06760182 Clinical Trial of TQH2722 Injection in Patients With Seasonal Allergic RhinitisSeasonal Allergic Rhinitiscompleted169
2025-04-30P1/P2noiVita SrlsNCT07110480 Combination of Equisetum Arvense and Palmitoylethanolamide (PEA) for the Management of Patients With Chronic Pain in a Before-after StudyChronic Pain; Chronic Pain (Back / Neck); Pain (Visceral, Somatic, or Neuropathic); Pain Managementcompleted50

← 2025-03 | 2025-05 →

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.